Canagliflozin ameliorates hypobaric hypoxia-induced pulmonary arterial hypertension by inhibiting pulmonary arterial smooth muscle cell proliferation

Article Oncology

SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways

Yan Wang et al.

Summary: SGLT2 inhibitors may have therapeutic effects on thyroid cancer by limiting glucose uptake and inhibiting tumor growth.

CANCER CELL INTERNATIONAL (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

SPARC, a Novel Regulator of Vascular Cell Function in Pulmonary Hypertension

Christine Veith et al.

Summary: This study provides evidence for the involvement of SPARC in the pathogenesis of human PH and chronic hypoxia-induced PH in mice, most likely by affecting vascular cell function.

CIRCULATION (2022)

添加到收藏夹

Review Medicine, General & Internal

Diagnosis and Treatment of Pulmonary Arterial Hypertension A Review

Nicole F. Ruopp et al.

Summary: Pulmonary arterial hypertension, a subtype of pulmonary hypertension characterized by pulmonary arterial remodeling, can progress to right heart failure and death if left untreated. Approved therapies targeting multiple biological pathways have significantly improved survival rates.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial

John A. Spertus et al.

Summary: Large traditional clinical trials have shown that sodium-glucose co-transporter 2 inhibitors can improve symptoms in heart failure patients. In a new trial conducted remotely (CHIEF-HF trial), canagliflozin was found to significantly improve symptoms in heart failure patients, regardless of ejection fraction or diabetes status.

NATURE MEDICINE (2022)

添加到收藏夹

Article Respiratory System

Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

Yi Tang et al.

Summary: Dapagliflozin reduces right ventricular systolic pressure and pulmonary vascular remodeling in a rat model of pulmonary arterial hypertension. However, combination therapy with dapagliflozin and sildenafil was not more effective than monotherapy with sildenafil in pulmonary arterial hypertension rats.

BMC PULMONARY MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration

Jochen Dutzmann et al.

Summary: Empagliflozin reduces proliferation and migration of SMCs in vitro, prevents neointima formation in vivo, and augments EC proliferation in vitro and re-endothelialization in vivo.

FRONTIERS IN CARDIOVASCULAR MEDICINE (2022)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Dapagliflozin reduces the vulnerability of rats with pulmonary arterial hypertension-induced right heart failure to ventricular arrhythmia by restoring calcium handling

Jinchun Wu et al.

Summary: This study found that dapagliflozin (DAPA) can reduce the vulnerability to ventricular arrhythmia in rats with pulmonary arterial hypertension-induced right heart failure by improving calcium handling in heart cells.

CARDIOVASCULAR DIABETOLOGY (2022)

添加到收藏夹

Article Cell Biology

The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion

Sergiy Sukhanov et al.

Summary: Chronic inflammation and oxidative stress play crucial roles in the development of vascular proliferative diseases. This study found that proinflammatory cytokine IL-17A can induce oxidative stress and inflammatory signaling in human aortic smooth muscle cells, which can be prevented by the SGLT2 inhibitor EMPA. EMPA exerts beneficial effects in reducing oxidative stress, inflammation, proliferation, and migration of SMC, suggesting its therapeutic potential in vascular proliferative diseases.

CELLULAR SIGNALLING (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Effects of Sodium-Glucose Co-Transporter 2 Inhibitors on Vascular Cell Function and Arterial Remodeling

William Durante et al.

Summary: SGLT2 inhibitors improve cardiovascular outcomes in patients with diabetes through various mechanisms such as increasing nitric oxide bioavailability, regulating endothelial cell function, and exerting antioxidant and anti-inflammatory effects.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Review Cardiac & Cardiovascular Systems